Here come the ads for Repatha®
If you have high cholesterol, you need to know about the results of Amgen's Repatha® study. Highly anticipated by cardiologists and insurers, the trial evaluated whether adding a PCSK9 inhibitor to statin treatment improves outcomes.
Here are the major take-aways the pharmaceutical company will want you to see:
- Adding Repatha® to statin treatment dramatically lowered LDL (bad) cholesterol - from an average of 92 mg/dL to 30 mg/dL.
- This cut the risk of heart attack and stroke by over 20 percent
- There was no increase in side effects, including muscle achiness, cognitive issues or diabetes
Here is what the pharmaceutical company will want to gloss over:
- There was no reduction in overall rates of death
- We don’t know the long term effects of having extremely low LDL levels – patients in the study were on the drug for less than 3 years and this medication is meant to be taken for life
- Repatha® costs $14,000 per year
What you should take away:
- This study adds to the consistent data that lowering LDL reduces heart disease risk, no matter what you use to get there
- If your doctor prescribes Repatha® and you have a high deductible, be prepared for sticker shock. And even if your insurer covers the drug, you may still be stuck with a very high co-pay
- Given the lack of long term side effect data, you should think of this drug as a last resort, not a first line option
- Food is always the better answer. It’s tried and true. It has no side effects. And when full of fiber, omega 3 fatty acids, antioxidants and plant sterols, it’s already extensively proven to lower LDL cholesterol and markedly reduce the risk of heart disease.
by Elizabeth Klodas MD, FACC
Get heart health tips and articles like this, delivered right to your email.
New articles every week.